Literature DB >> 6514433

IgG and IgM pneumococcal polysaccharide antibody responses in infants.

D J Barrett, C G Lee, A J Ammann, E M Ayoub.   

Abstract

The ontogeny of human antibody responses to pneumococcal polysaccharide antigens was studied by determining whether the age at immunization affects the level and/or immunoglobulin isotype of antibody produced. Twenty-nine healthy infants between 2 and 18 months of age and 13 normal adults were studied. Responses were found to vary markedly with the age at the time of immunization and with the pneumococcal serotype tested. Three general patterns of isotype-specific antibody response were observed in the infants: a high response in IgG antibody occurred as early as 2 months of age following immunization with type 3 pneumococcal polysaccharide; little or no response was noted in either IgG or IgM antibody with types 6, 18, and 19; and intermediate responses with IgM antibody increases greater than IgG increases were found for type 23. These data suggest that different factors control the immunologic response of infants to various pneumococcal polysaccharide serotypes following immunization at various ages.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6514433     DOI: 10.1203/00006450-198411000-00001

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  18 in total

1.  B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity.

Authors:  T L McCool; C V Harding; N S Greenspan; J R Schreiber
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Lymphocyte subset populations in children with polysaccharide antibody deficiency following cardiac transplantation.

Authors:  A R Gennery; D Barge; G P Spickett; A J Cant
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

Review 3.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

4.  Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors.

Authors:  B L Ferry; S A Misbah; P Stephens; Z Sherrell; H Lythgoe; E Bateman; C Banner; J Jones; N Groome; H M Chapel
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

5.  Guillain-Barré syndrome associated with IgM anti-GM1 antibody following Campylobacter jejuni enteritis.

Authors:  K Sugita; M Ishii; J Takanashi; H Niimi; N Yuki
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

6.  Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls.

Authors:  M A Avanzini; A M Carrà; R Maccario; M Zecca; G Zecca; A Pession; P Comoli; M Bozzola; A Prete; R Esposito; F Bonetti; F Locatelli
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

7.  CD21/35 promotes protective immunity to Streptococcus pneumoniae through a complement-independent but CD19-dependent pathway that regulates PD-1 expression.

Authors:  Karen M Haas; Jonathan C Poe; Thomas F Tedder
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

8.  Levels of anti-pneumococcal antibodies in young children in Papua New Guinea.

Authors:  W S Pomat; T A Smith; R C Sanders; C S Witt; J Montgomery; D Lehmann; M P Alpers
Journal:  Epidemiol Infect       Date:  1993-08       Impact factor: 2.451

9.  Direct evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency.

Authors:  A B Bjornson; J S Lobel
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

10.  Evolution of the subclass of IgG antibody to type 3 pneumococcal polysaccharide during childhood.

Authors:  D A Schatz; D J Barrett
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.